Callori Fred 4

What Happened

• Fred Callori, a director of LeonaBio, received a grant of a derivative award (an option to acquire) 56,000 shares on 2026-05-05. The filing reports an acquisition price of $0.00 (no cash paid at grant) — this was an award, not a sale or immediate purchase. The award vests monthly over 36 months per the issuer's 2026 Equity Incentive Plan.

Key Details

• Transaction date: 2026-05-05; Form 4 filed: 2026-05-07 (timely filing).
• Security: derivative (option) to acquire 56,000 shares; reported acquisition price $0.00.
• Vesting: monthly over a 36-month term (footnote F1).
• Shares owned after transaction: not specified in the excerpt of the filing.
• Footnote: F1 states vesting is contingent on continued service as a “Service Provider” under the 2026 Equity Incentive Plan.
• Filing timeliness: filed within the standard Form 4 timeframe (appears timely).

Context

• This was a grant of an option-like award (a future right to acquire shares) rather than an immediate purchase or sale. Such grants compensate and retain executives/directors; they do not represent immediate cash proceeds or liquid stock sales. Check the full Form 4 or company disclosures for total insider holdings, exercise price (if any), and plan terms if you want more detail.